Read Gene

Read Gene Financing Cash Flow

The Net Financing Cash Flow of Read Gene (RDG.WA) as of Nov 5, 2026 is 46,050.00 PLN. In the previous year, Net Financing Cash Flow was 3.31 M PLN — a change of -98.61% (lower).

Financing Cash Flow

46,050.00PLN

YoY

-98.61%

Last updated:

Net Financing Cash Flow of Read Gene is 2020 46,050.00 PLN. Net Financing Cash Flow of Read Gene was 2019 3.31 M PLN. It decreases by -98.61% lower compared to the previous year.

The Read Gene Financing Cash Flow history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Financing Cash Flow
Date
Financing Cash Flow
Jan 1, 2014
260,000.00 PLN
Jan 1, 2015
1.60 M PLN
Jan 1, 2016
3.42 M PLN
Jan 1, 2017
290,030.00 PLN
Jan 1, 2018
1.85 M PLN
Jan 1, 2019
3.31 M PLN
Jan 1, 2020
46,050.00 PLN
The Read Gene Financing Cash Flow history
YEARFinancing Cash FlowYoY
46,050.00PLN-98.61%
3.31 MPLN+79.20%
1.85 MPLN+536.37%
290,030.00PLN-91.52%
3.42 MPLN+113.16%
1.60 MPLN+516.83%
260,000.00PLN—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Read Gene Stock analysis

What does Read Gene do? Read Gene SA generates revenue through medical research and testing services, focusing on malignant tumor detection, prevention, and treatment. The company offers breast cancer, colon cancer, and prostate cancer tests, along with medical consultancy, DNA tests, and supplements. Its subsidiary Dieta Antyrakowa Read-Gene Sp. z o.o. supports these services, while major shareholder GEN-PAT-MED Sp. z o.o. provides strategic backing. Clients include patients seeking cancer diagnostics and preventive care, as well as healthcare providers integrating these tests into treatment protocols. The firm's chemoprevention, clinical trials, and genetic testing specialties drive product sales to hospitals, clinics, and individual consumers. Breast cancer, colon cancer, and prostate cancer tests are key revenue streams, complemented by DNA tests and supplements. Medical consultancy services cater to institutions requiring expert guidance on cancer-related health strategies. Read Gene SA's product portfolio is structured around three core fields: chemoprevention, clinical trials, and genetic testing. The company monetizes genetic testing services, particularly for breast, colon, and prostate cancers, alongside DNA tests and supplements. Healthcare institutions and private clients form the primary customer segments, with Dieta Antyrakowa Read-Gene Sp. z o.o. serving as the operational arm for these offerings. Read Gene is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Read Gene stock

Net Financing Cash Flow of Read Gene is 46,050.00 PLN in 2020.

Net Financing Cash Flow of Read Gene changed from 3.31 M PLN to 46,050.00 PLN, representing a -98.61% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Net Financing Cash Flow Read Gene since 2006 – with annual values, charts, and detailed analysis.

Financing cash flow measures cash flows from debt issuance/repayment, equity transactions, and dividend payments.

Net Financing Cash Flow's PLN is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Net Financing Cash Flow's Read Gene historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Cash Flow — Read Gene

Operating Cash FlowCapital ExpendituresFree Cash FlowFCF per ShareDividends PaidShare BuybacksInvesting Cash FlowFinancing Cash FlowCapEx / RevenueCash Flow per ShareStock-Based CompensationChange in Working CapitalAcquisitions (Net)Net Change in CashCapEx/OCFFCF/Net IncomeFCF ConversionCash ConversionTotal Shareholder PayoutCapEx/D&A

All Key Metrics — Read Gene